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     Colorectal cancer is the second leading cause of cancer deaths, in the United States.  
Colorectal cancer screening decreases mortality.  Uninsured patients are less likely to be 
screened.  Screening interventions must be implemented to be effective and less is known 
about the implementation process, in community clinics that serve the poor. 
     Implementation science is the study of methods that promote the uptake of research 
findings into routine practice in an effort to improve health services.  A feasibility study has 
been proposed to evaluate implementation of a multi-level intervention and also to determine 
the effect that a provider reminder and patient education has on screening colonoscopy rates.  
A hybrid study has been designed to correlate implementation outcomes with clinical outcomes 
and a randomized component will look specifically at the impact of patient education. 
     This feasibility study was constructed for adaptability to other clinic sites that may have 
budgetary constraints limiting effectiveness research.  Its potential impact may be to further 
define the importance of implementation and the impact on colorectal cancer screening in the 
underserved population.  Results of this preliminary trial are expected to lead to additional 
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translational studies related to cancer prevention and in collaboration with formal research 
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CHAPTER 1: INTRODUCTION TO PROPOSAL 
 
 
Section 1.1 Rationale 
 
     Colorectal Cancer (CRC) is the second leading cancer killer in the United States.  Colorectal 
cancer screening (CRC-S) by colonoscopy can diagnosis the disease earlier when treatment is 
more effective and potentially curable or prevent the disease from occurring by removing pre-
cancerous polyps and thus, save lives.  The rate of CRC-S in those without health insurance is 
less than that of the general adult population.  Multi-level interventions (MLIs) that are attentive 
to the intrapersonal, interpersonal and organizational constructs of the Social Ecological Model 
(SEM) and linked to theories of behavioral change are proposed to improve cancer screening, but 
there are few confirming trials.  In addition, there is a large gap between what is known in 
research and what is considered effective in clinical practice.  It may take years for scientifically 
proven facts to trickle down through translational trials, emerge as guidelines and then become 
adopted by healthcare providers.   
     Hybrid studies blend the process of researching clinical effectiveness and implementation 
research (IR) and may be a more efficient method to transfer useful information into the hands of 
organizational leaders and decision makers.  Implementation outcomes (IOCs), if they relate to 
clinical outcomes may be valuable markers and serve as intermediary predictors of intervention 
success or failure. 
     A randomized trial is expected to result in a clear definition of the role of patient education 
prior to provider interaction in encouraging screening colonoscopy.  As a component of a MLI, 
patient education and provider reminders should lead to improved colonoscopy referrals and 
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completed procedures.  Furthermore, a quantitative analysis of implementation outcomes is 
expected to predict clinical results.  The impact of these intended results will be to broaden the 
scope of similarly designed hybrid trials and to obtain funding for a future pilot study to expand 
upon our knowledge of implementation science. 
Section 1.2 Statement of Problem  
 
      Often MLIs are designed to improve cancer screening rates in a variety of clinical settings, 
but they have not been studied only in an uninsured population.  In addition, previous studies 
have not been designed to determine the singular effect of only one intervention.  There is also 
minimal evidence that correlates quantitative implementation data with clinical data, as it 
pertains to CRC-S. 
Section 1.3 Objectives & Research Questions 
• Can a MLI be implemented effectively in a community clinic setting to improve 
colonoscopy screening rates, in an uninsured patient population?  
• Can an individual intervention (patient education) be analyzed in a randomized manner 
and compared to a control group during implementation of a MLI to improve CRC-S? 
• How do the implementation outcomes of patient education (intrapersonal level) and 
provider reminders (interpersonal level) correlate with the clinical outcomes of 









CHAPTER 2: BACKGROUND 
 
Section 2.1 Colorectal Cancer Incidence 
     CRC is the second most common cancer and the second leading cause of cancer-related 
deaths affecting both men and women, in the United States.   In 2016, 141,000 people were 
diagnosed with CRC and greater than 52,000 people died of this disease.1  
     CRC develops as a progressive process over 10-15 years, in most cases.  Benign polyps begin 
their growth in the lower gastrointestinal tract (colon and rectum) and ultimately transition into a 
neoplastic tumor that can spread throughout the body, ultimately taking the life of an individual.  
Screening colonoscopy is effective because of two reasons.  It can remove the pre-cancerous 
polyps, preventing cancer and it can diagnose CRC at an earlier stage, possibly before it has 
metastasized, when it is more amenable to treatment. 
     By 2019, there were 776,120 men and 768,650 women alive in the United States with a 
history of CRC, some of whom were cancer-free, while others still had evidence of cancer and 
may have been undergoing therapy.  Lifetime risk and median age at diagnosis of CRC is 4.4% 
and 66 years for men and 4.1% and 69 years for women.  Relative survival rates are 64% at 5 
years and 58% at 10 years, following diagnosis of CRC.  The most important predictor of 
survival is the stage in which CRC is diagnosed.  For example, the 5-year survival is 90% if the 
disease is diagnosed early, when localized to the colon (stage 1 & 2).  However, if CRC is 
diagnosed once it has spread to the regional lymph nodes (stage 3) or beyond (stage 4) the rate of 
survival drops to 71% and 14%, respectively.  Low socioeconomic status and black race are two 
major associated factors with advanced stage of diagnosis.2  
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     The incidence and mortality of CRC is related to race/ethnicity that is largely a factor of 
socioeconomic status, 20% and 40% higher for blacks when compared to whites (2018 median 
income $41,361 versus $70,642, respectively). The poorest individuals are more likely to be 
diagnosed with CRC, related not only to prevalence risk factors of CRC (smoking, obesity), but 
also due to a difference of CRC-S.  Today, the incidence rate of CRC is highest in parts of the 
South, Midwest and Appalachia, with state averages ranging from 30 to 49 (per 100,000 
persons).  The geographic racial patterns are similar, suggesting the importance of 
socioeconomic status in determining cancer disparity.3  
     The incidence of CRC increased through the mid-1980’s, but then has declined attributed 
equally to societal reduction in some risk factors, such as smoking and the widespread uptake of 
CRC-S with colonoscopy.  However, this reduction of incidence has not been as apparent in 
marginalized communities during this same time period, most likely due to a combination of 
delayed access and acceptance of CRC-S, as well as changing socioeconomic risk factors 
affecting the prevalence of CRC.4  
Section 2.2 Colorectal Cancer Screening Methods 
     The US Preventative Services Task Force (USPSTF) has recommended several screening 
tests, stool-based and direct visualization.  The stool-based tests include a high sensitivity 
guaiac-based fecal occult blood test (FOBT), a fecal immunochemical test (FIT) and a stool 
DNA test.  The FOBT and FIT detect blood in the stool, but by different methods.  The FOBT 
identifies the blood via a chemical reaction, whereas FIT uses antibodies for detection.  Stool 
DNA tests detect biomarkers of cancer cells shed from the lining of the lower gastrointestinal 
tract.  Currently, the FIT test is more commonly used and is recommended annually, with the 
caveat that any positive finding is followed up by a diagnostic colonoscopy to complete the two-
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part screening process.  Direct visualization screening studies include colonoscopy every 10 
years, sigmoidoscopy (evaluation of the distal third of the lower gastrointestinal tract) every 5 
years, in conjunction with an annual FIT and CT colonography (two-dimensional radiographic 
study) every 5 years.  The administration and details of these screening tests are beyond the 
scope of this paper, but suffice it to say, all have been studied extensively and are included in the 
most up to date recommendations by the USPSTF (October 2020) and adopted by many cancer 
and clinical specialty societies.5    
     In addition, the USPSTF has lowered the age for CRC-S to 45 years from 50, based upon a 
recent trend for increasing risk of CRC in younger adults (20.0 new CRC cases per 100,000 
persons ages 40-49 years, 47.8 new CRC cases per 100,000 persons ages 50 to 59 years and 
105.2 new cases per 100,000 persons age 60 years and older).  Modeling has shown an increase 
in life years gained and a decrease in CRC cases and deaths, when compared to starting 
screening, at age 50.  On the other end of the spectrum, CRC-S becomes less favorable if 
extended beyond age 75 years among average-risk adults, previously adequately screened.6  
     The data that CRC-S decreases CRC mortality is based upon historical randomized control 
trials that demonstrated this finding with both FOBT and sigmoidoscopy, neither of which are 
commonly used today.  The more complete colonoscopy effectiveness is only indirectly inferred 
from the sigmoidoscopy trials. Whereas FIT effectiveness is assumed given the fact that studies 
have shown increased sensitivity when compared to FOBT.7  
     The National Colorectal Cancer Roundtable, an organization co-founded by the American 
Cancer Society and Center for Disease Control, has set an earlier goal of 80% of all adults to be 
screened.8  Healthy People 2030 goals, as recommended by the Advisory Committee on National 
Health and Promotion and Disease Prevention has set a target of 74.4% for CRC-S, following a 
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2020 age-adjusted national baseline of 65.2%.9   Both campaigns have increased CRC-S, as 
identified by the self-reporting National Health Interview Survey, noting incremental gains from 
2015 to 2018 (Table 1.).  However, this same national survey shows a significant drop-off when 
comparing persons who are uninsured.10  
 
Table 1. CRC-S (%), Adults 50 Years and Older, US, 2015 & 2018 
YEAR/CRC-S 
METHOD 
FOBT or FIT COLONOSCOPY UTD** UTD: NO INS 
2015 7 60 63 25 
2018 11 61 66 30 
 
**UTD (Up to Date): FOBT or FIT within the past year or sigmoidoscopy within the past 5 
years or colonoscopy within the past 10 years 
 
 
In addition, it should be noted that self-reported screening rates from national surveys are 
probably overestimates of actual CRC-S.11  
     Recommendations on FIT testing for CRC-S were established by the American Society for 
Gastrointestinal Endoscopy (ASGE), in 2017.  Evidence supporting FIT included the sensitivity 
and specificity data for detecting CRC of 74% and 96%, respectively.  However, the sensitivity 
for detecting advanced adenomatous polyps (defined as any adenoma > 10mm or with villous or 
high-grade dysplastic features) ranged from 25% to 56% and the specificity ranged from 68% to 
96%, using colonoscopy as the gold standard, in average-risk patients.  What is not known is the 
clinical importance of missing advanced pre-cancerous lesions, the rate of subsequent 
identification on annual stool testing and the impact on CRC-related morbidity, mortality and 
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cost.  Randomized control trials are currently ongoing comparing FIT to screening colonoscopy, 
with CRC mortality as the endpoint.  The CONFIRM trial (Colonoscopy Versus 
Immunohistochemical Test in Reducing Mortality from Colorectal Cancer) postulates that 
screening colonoscopy will result in a 40% reduction in CRC mortality over 10 years relative to 
annual FIT testing.12  
     At the time of the ASGE report there were 26 FIT manufacturers, 13 FIT devices approved by 
the Federal Drug Administration that had stool hemoglobin detection thresholds ranging from 6 
to 300 ug/g and with first round screening participation rates of 48.2% to 62.6%.  Available 
online FIT information lists many conditions in which the test may not be helpful, possibly 
reflecting other diagnoses: rectal bleeding or blood in your stool, changes in your bowel habits 
that last more than a few days, unexplained belly pain or cramping, urgency to have a bowel 
movement that doesn’t go away after passing stool, unexplained weakness, tiredness or 
significant weight loss, or the diagnosis of anemia.13  
     Current guidelines recommend the three screening strategies described above.  However, the 
CRC-S process is complex and there are gaps in our knowledge that impact how these evidence-
based interventions (EBIs) are ultimately incorporated into the clinical setting.  FIT screening 
programs may be an option for healthcare organizations and practices due to patient acceptability 
and less up-front costs.  However, only superior testing formats should be used, providers must 
order the test appropriately, annual follow-up must be high and diagnostic colonoscopy is 
necessary in a timely manner after an abnormal test is achieved.  Optimization of this form of 
CRC-S testing is paramount for success. 
     The Multi-Society Task Force recommends a FIT cut-off value of <20gb/g of feces to ensure 
the highest accuracy and cost-effectiveness.  In addition, providers must play a key role in 
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ordering the proper test and educating patients about stool collection.  FIT should be not be 
ordered when other clinical conditions are suspected or in patients with multiple comorbidities 
that would preclude diagnostic colonoscopy, if the test was abnormal.  Mailed FIT interventions 
as the only form of CRC-S process should be used with caution as certain patients may require 
additional support.  Repeating an abnormal FIT is discouraged as a subsequent normal (false 
negative) FIT could lead to missing an advanced adenoma or CRC.  An abnormal FIT should 
prompt diagnostic colonoscopy, even if performed recently, since poor preparation could have 
resulted in a falsely negative colonoscopy exam initially.  Lack of colonoscopy follow-up or 
delayed follow-up greater then 10 months after a positive FIT is associated with increased 
mortality from CRC due to delayed diagnosis.  Healthcare network referrals may lead to lack of 
coordination with GI specialists.  Policy discrepancies may exist with insurers not paying for a 
“diagnostic” colonoscopy following an abnormal FIT, in contrast to full reimbursement for a 
screening study.  Adherence to an annual FIT screening is necessary to ensure effectiveness and 
is of concern following several reports of <50% compliance.  FIT testing quality assurance by 
organizations using this form of CRC-S is necessary to minimize inappropriate use, ensure 
follow-up diagnostic colonoscopy and confirm appropriate adherence rates over time.14  
     The National Cancer Institute has established a consortium to foster coordinated research 
efforts regarding the transdisciplinary approach needed to evaluate CRC-S more thoroughly.  
The Population-Based Research Optimizing Screening through Personalized Regimens 
(PROSPR) has been established as a central data repository and one of the integrated healthcare 
systems, Parkland-UTSW, in Dallas, Texas is the sole, safety-net provider for the under-insured 
and uninsured county residents.  A CRC-S system process model has been developed for 
analysis of patient, provider, organization and network level factors impacting clinical outcomes 
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of the screening process.15 Implementation strategies aimed at these levels, as well as effective 
monitoring and feedback measures are crucial for an effective CRC prevention program.  
Another PROSPR member, the Kaiser Permanente Northern California group adopted the 
integrated process and more than doubled their 2006 baseline CRC-S rate of 40% to 83%, by 
2015.  Participation was enhanced, screening disparities decreased and the focus on quality 
decreased over-screening, complications and poor follow-up.  Their focus was CRC-S delivery 
and less on the proven screening modalities.  An organized rather than an opportunistic approach 
was effective in increasing and maintaining screening levels at national goals.16  
Section 2.3 Federally Qualified Health Centers 
     The Health Resources and Services Administration, an agency of the US Department of 
Health and Human Services funds Federally Qualified Health Centers (FQHCs) that care for 
patients that have Medicare, Medicaid, private health insurance and/or the uninsured.  About 30 
million persons (1 in 11 US citizens), 1 in 5 uninsured persons and 1 in 3 living in poverty rely 
on their services for health care and prevention measures.  Participating FQHCs must report 
certain information via the Uniform Data System Report.  Program participants identified 
between 14-23% of their patient population being uninsured, in 2019.17 The North Carolina 
FQHCs, serving more than 610,000 patients reported only a 46% CRC-S rate during this same 
time period.18 However, not all community clinics can meet the FQHC requirements and 
therefore lack additional support to provide services to the indigent population.  This additional 





Section 2.4 Cost-effective Analysis 
     One way in which healthcare decision-makers can identify interventions that yield the 
greatest benefits given resource constraint is by using a cost-effective analysis.  Typically, a 
mathematical model is used to track benefits or harms, as well as the associated cost of 
interventions and those of the side-effects.  An incremental cost-effectiveness ratio compares the 
quality-adjusted life-years gained comparing two intervention strategies to each other, in the 
denominator and the additional cost of that strategy, in the numerator.  The World Health 
Organization (WHO) general principles recommend population screening when costs and 
benefits are balanced.  Industrialized countries have come to adopt an intervention that provides 
an additional year of life at an incremental cost of $50,000 or less, acceptable.  All of the CRC-S 
tests analyzed in a systemic review (annual FOBT, sigmoidoscopy every 5 years and in 
conjunction with annual FOBT and colonoscopy every 10 years) were all noted to be acceptable.  
FOBT was estimated between $5,691 and $17,805 per life-year gained, sigmoidoscopy and 
FOBT between $13,792 and $39,359 per life-year gained and colonoscopy between $9,038 and 
$22,012 per life-year gained.19  
     In general, the differences in life-years gained between screening strategies are not 
significant, a finding that shifts the focus upon which test-specific adherence is most likely, 
rather than cost-effectiveness as the prime indicator of importance.  Analyses of cost-
effectiveness typically assumes complete adherence to the screening strategy.  While that may be 
the case with FOBT during the first year when compared to colonoscopy screening, 
implementation of this screening strategy requires an annual commitment over 10 years to equal 
the same benefit of a singular colonoscopy during that same period.  Adherence to FOBT may 
decline over time.  Longer trials are necessary to determine which screening modality has the 
 11 
best adherence track record.  In addition, efficacy of randomized controlled screening studies of 
FOBT are often performed with specific follow-up protocols that ensure quality control and 
adherence, often lacking in real-world effectiveness trials.  Whereas FOBT adherence may be 
80% under ideal settings, only 50% may actually follow-up in clinical settings.20 Also, if a 
patient has a positive stool test, then direct visualization of the colon is necessary, requiring 
diagnostic colonoscopy.  A recent study conducted within a safety-net health system revealed 
42.3% of positive FIT patients failed to have follow-up colonoscopy within one year related to 
patient-level factors (57%), provider-level factors (18%), system-level factors (22%) and 
unknown factors (3%).21 This finding takes on added significance given precancerous or 
malignant lesions were identified on subsequent direct visualization examinations 48.6% of the 
time.22  These results suggest that test-specific adherence, rather than cost-effectiveness predict 
the better CRC-S option.  “The best test is the test that gets done well.”23 
     The cost of CRC treatment has increased over 200% from the 1990’s, dependent upon the 
stage of disease and continues to rise due to newer, more effective chemotherapeutic agents, 
especially the monoclonal antibodies drugs approved for metastatic CRC.  CRC-S costs have not 
risen that dramatically.  Therefore, the cost-effectiveness of CRC-S is becoming increasingly 
attractive financially due to the treatment savings from preventing advanced CRC.    
     An earlier study, using a Markov computer model process was used to compare the three 
main options for CRC-S (FOBT, sigmoidoscopy and colonoscopy).  Better compliance and less 
testing were the main factors in concluding colonoscopy, every 10 years was the most effective 
primary screening strategy.  A follow-up study by the same author found repeat colonoscopy at 
10 years, when compared to no screening has a cost-effectiveness ratio (CER) of $10,983 per life 
year saved.  The CER is calculated as the difference between the costs (no screening versus 
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multiple colonoscopies) divided by the difference in effectiveness (life years saved).  Repeat 
screening colonoscopies saved more lives, obviously then no CRC-S, whatsoever.  The 
interesting comparison was to a singular screening colonoscopy, at age 60 that had a much better 
CER ($2981) and in fact paid for itself (-$1199), assuming a higher cost of cancer care 
($60,000).  Although the cost of serial screening colonoscopies is mostly affected by the cost of 
each procedure and possible complications, a singular colonoscopy is most sensitive to a higher 
cost of cancer care, a significant fact given the expense of newer cancer drugs offered to treat 
advanced disease.24  A recent observational study seems to suggest that a high-quality 
colonoscopy (complete exam with a good bowel preparation) yielded a profound and stable 
reduction in CRC incidence during a 17 year follow-up, beyond the current CRC-S 
recommendation of 10 years.25  
Section 2.5 Implementation & Cost-Effectiveness 
     A cost-effective analysis can also be performed to evaluate CRC-S interventions during 
implementation of the screening process.  Published accounts are difficult to compare given the 
various MLIs, screening methods and economic calculations.  FIT was studied at several FQHCs 
using the implementation strategies of patient and provider reminders, navigation, incentives, 
reduction of structural barriers and provider assessment and feedback with implementation costs 
ranging from $66.79 to $144.65 per additional person that returned the FIT kit.  These studies 
used a pre and post design without a concurrent comparison group and with detailed 
implementation procedures that enhanced the confidence of their findings.26 An economic 
assessment of patient navigation to colonoscopy concluded that when a non-nurse performed this 
service, implementation costs per additional patient screened ranged from $88 to $215 and when 
the procedure was factored in, $148 to $359, depending upon the no-show estimated rate of 0% 
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to 50% and a navigation rate of 85%.27 Another study looking at navigation in a group of low-
income adults found colonoscopy to be cost-effective using an incremental cost-effectiveness 
ratio (ICER).  Pre and post implementation data were collected on the difference in percentage of 
the patients screened and the incremental cost.  The ICER was $725, a figure lower than the 
Medicare reimbursement for a single colonoscopy.28  
Section 2.6 Health Network Costs 
     Treatment for CRC is expensive, especially in the advanced stages.  Analysis of the 
Surveillance, Epidemiology and End Results (SEER)-Medicare data, from 2007-2013, shows 
that when matching cancer-attributable costs to phase of care, the initial phase (first 12 months 
after diagnosis) averaged $55,845 per patient and the end-of-life phase (last 12 months before 
death) averaged $92,476 per patient.  During the continuing phase (the time in between), the 
average annual expense was $5,313 per person.  In addition, the initial phase therapy costs 
correlated with the stage of diagnosis, $25,425 (stage 0, pre-cancerous), $37,200 (stage 1), 
$52,756 (stage 2), $76,639 (stage 3) and $113,889 (stage 4).29  
      Another way to look at the cost of CRC is through hospitalization data.  The Healthcare Cost 
and Utilization Project characterized hospitalizations related to CRC, in 2006.  There were 
151,900 admissions with the principal diagnosis of CRC (25.9% presented urgently, via the 
emergency department), a mean cost per hospitalization of $17,000 and an aggregate cost of $2.6 
billion.  Uninsured patients accounted for 3.2% of this population and a potential loss of $80 
million to hospitals and healthcare networks.30 Unlike the majority of cancers, CRC is 
considered preventable given the screening methods described above.  Hospitalizations and 
treatment of advanced disease is far more expensive than the cost of the CRC-S programs.   Not 
providing CRC-S programs for marginalized communities and the uninsured or under-insured 
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will continue to be a financial drain on the US healthcare system and a potential burden on 
individuals unfortunately diagnosed with this often debilitating and deadly disease. 
Section 2.7 Multi-Level Intervention Theory 
     The SEM provides justification for MLI to improve rates of CRC-S.  At the core of the model 
is the individual, encircled by the interpersonal, organizational, community and policy influential 
rings that impact CRC prevention.  Ultimately, this program design will focus upon strategies 
impacting the first three rings, understanding that implementation of public health activities at all 
levels will maximize the impact of an intervention.  At the intrapersonal level, the patient is the 
central figure that incorporates educating the individual about the risks and benefits of CRC-S, 
attempting to change attitudes and beliefs, while reducing barriers by providing affordable and 
convenient services.  The second ring encompasses the first and concentrates on the interpersonal 
level, activities that attempt to change personal behavior by affecting social and cultural norms.  
Included within this category are family members, friends, healthcare providers, community 
health workers and patient navigators.  Examples of interpersonal interventions include CRC-S 
recommendations from providers, patient reminders about screening and navigator assistance to 
aid in scheduling and complying with the colonoscopy procedure.  The organizational level 
provides the context of the third ring.  It incorporates CRC-S activities intended to adjust 
individual behavior through organizational and network processes.  Healthcare facilities, 
including provider offices, community clinics, hospitals, local health departments and 
professional organizations may all be a part of the messaging and support promoting 
preventative services.  Provider reminders, provider assessment and feedback and adopting 
worksite actions are all examples of activities, at this level.31  
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     Individuals live and seek healthcare in a complex environment that ultimately shapes their 
behavior regarding seeking preventative care.  By combining a system model, such as the SEM 
with a behavioral change model, such as the Theory of Planned Behavior, one is then able to 
expand the MLIs to consider independent interactions that affect the individual.  For example, at 
the organizational level health networks and the community influence control beliefs and the 
perceived behavioral control an individual has available to choose or avoid CRC-S.  At the 
interpersonal level healthcare providers, family and friends impact normative beliefs and the 
subjective norm an individual experiences, regarding these same preventative measures.  Finally, 
at the individual level, patient education addresses behavioral beliefs that influence an attitude 
toward the behavior.  In this way, incorporating system level ideology with a behavior model, 
perceived control, subjective norms and individual attitudes create an intention toward cancer 
prevention and subsequently CRC-S.32  
     Scientific evidence of intervention effectiveness guides healthcare providers to implement 
best practices for their patients.  In general, these behaviors are measured by their prevalence or 
incidence within a given population: for example, the incidence of CRC-S in patients who seek 
healthcare at a particular community clinic.  Improving the preventive measures that impact 
individual and public health depend upon fundamental behavioral change interventions.  The 
Health Belief Model is another behavioral theory associated with decisions individuals make 
regarding cancer screening.  Perceived susceptibility and benefits of CRC-S impact behavior 
most commonly.  Cues to action, especially physician recommendation for screening also 
encouraged adherence to a screening regiment.  Perceived barriers may include both structural 
(lack of access, cost) and/or psychosocial (embarrassment, fear) reasons.  Interestingly, 
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perceived severity of CRC was inversely associated with screening.  Denial of a potential serious 
disease was found more predictive than a behavior that could prevent that same disease.33  
     Another framework for understanding behavior is the COM-B (Capability, Opportunity, 
Motivation – Behavior) system that forms the hub around which a behavioral change wheel 
(BCW) is designed that incorporates nine interventions and seven policy categories, linked to 
behavioral change.  The COM-B system incorporates capability (physical and psychological 
capacity to engage in an activity), motivation (cerebral processes that energize behavior, 
including habits, emotional and analytical decisions) and opportunity (contextual factors that 
prompt or make possible a certain action).  This theory aggregates 19 other frameworks to link 
interventions to behavioral targets by incorporating context into design.  The BCW focuses upon 
motivation in context in an attempt to predict what approach can target behavioral change and 
then what intervention function may be effective to bring about that change.  “Behavior in 
context, is thus the starting point of intervention design.”34  
     The SEM in conjunction with behavioral models provide compelling justification for MLIs 
but fail to interject guidance about how various interventions can be used in a synergistic or 
complimentary manner.  The fundamental insight is that determinants at different levels 
(intrapersonal, interpersonal, organizational, community and policy) interact and influence 
human behavior and clinical outcomes.  This systems theory is based upon two basic principles: 
the first one being that health depends upon the complex interaction of personal factors and 
multiple aspects of physical and social environments and the second one that the multiple factors 
are interdependent and can mutually affect one another.  However, more interventions do not 
always translate into more effect, especially if they do not work together.  In this regard, 
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intervention designers could mistakenly combine MLIs in trials that produce scattered, redundant 
or opposing results.35 
     Causal models are representations using logic to describe system behavior used to clarify the 
relationships between determinants and outcomes.  It is beyond the scope of this paper to detail 
the five strategies utilized in MLI research (accumulation, amplification, facilitation, cascade and 
convergence).  However, one in particular, the convergence strategy, has particular implication 
in the program design described later in this paper and will be discussed briefly, here.  Using this 
strategy, interventions at different levels exhibit mutual interdependence, whereby they reinforce 
each other by altering patterns of interaction among two or more target audiences.  For example, 
a physician-directed and patient-directed intervention may mutually reinforce each other to 
promote a change in the physician-patient interaction and lead to a specific desired outcome (see 
diagram below).  The convergence strategy of the causal model complements other intervention 
planning models and provides a starting point for assessing how particular combinations of 
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     The Community Preventative Services Task Force (CPSTF) published The Guide to 
Community Preventative Services that outlines the MLIs of CRC-S, in 2016.   They 
recommended including two or more interventional strategies or reducing two or more structural 
barriers and delivered by healthcare networks, community organizations or both.  Strategies 
identified were increasing community demand (client reminders, client incentives, media and 
group or one-on-one education), improving community access (reducing structural barriers and 
client out-of-pocket costs) and increasing provider screening service delivery (provider 
assessment, incentives and reminders).  The CPSTF recommendation is based on evidence from 
a systemic review of 56 CRC-S studies and noted that multicomponent interventions increased 














colonoscopy screening 10.2% and FOBT 7.7% and were independent of the baseline screening 
level.  Studies that used greater than five approaches were associated with larger increase in 
CRC-S.  These findings were considered applicable to populations without insurance, 
community health centers and FQHCs.37  
Section 2.8 Colorectal Cancer Screening Interventions 
     An inclusive discussion of all interventions that may be implemented in cancer screening 
programs is beyond the scope of this paper.  However, two deserve mention that will be 
incorporated in the program design to be described herein: patient education (decision aids) and 
provider reminders.  Patient education has been used to improve the suboptimal decision making 
of CRC-S.  Mainly in the form of videos or printed materials, a recent meta-analysis found that 
decision aids were associated with improved screening when compared to controls.38 There are 
conflicting results in the literature regarding provider reminders promoting patient compliance 
with CRC-S.  In two earlier randomized trials, stool testing for occult blood was found to 
increase, but not sigmoidoscopy and in another, all forms of CRC-S were similar when 
comparing a reminded group of physicians and a control group, (41.9% and 40.2%, p=0.47).39 
However, more recently the CPSTF Community Guide reported stool testing and screening 
sigmoidoscopy are supported by reminders, but there was insufficient evidence for screening 
colonoscopy.40  
Section 2.9 Implementation Science  
     In review of the background material presented, scientific evidence has proven CRC-S 
reduces the incidence of CRC, decreases mortality and is cost effective.  The benefits of this 
form of cancer prevention are muted in patients without health insurance and who seek care in 
community centers and FQHCs across the country.  It is also not certain which is the best 
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screening test for CRC: annual FIT, sigmoidoscopy every five years in conjunction with annual 
FIT, or colonoscopy every 10 years, although the most recent evidence favors colonoscopy.  In 
addition, even less is known what interventions based upon the SEM and behavioral change 
theories can alter the direction of clinical practice that bring the most promising ideas into the 
reality of patient care.   Furthermore, while MLI strategies may seem intuitively superior to a 
single level intervention, the evidence is mixed.41    This may be due to dyssynergy based on a 
causal modeling or contextual barriers to EBI that operate beyond the realm of an individual 
provider.42   
     Many interventions heralded as effective in healthcare research studies fail to materialize 
across multiple contexts.  It may be that up to two-thirds of organizational change efforts fail, 
due to barriers of implementation that may arise at multiple levels, including the patient level, 
the provider level, the organizational level or the market level.  The extent to which 
implementation is effective will lead to optimization of intervention, sustainability and 
dissemination.  The Consolidated Framework for Implementation Research (CFIR) was 
established to formulate a framework of common constructs from published theories.  As the 
RE-AIM framework is used to evaluate interventions in terms of Reach, Effectiveness, 
Adoption, Implementation and Maintenance, the CFIR delves into the Implementation 
component.43  
     The CFIR has five major domains: the intervention, inner and outer setting, the individuals 
involved and the process by which the intervention is accomplished (See Figure 2).  The main 
goal of the framework is to build knowledge into reasons implementation fails or succeeds.  The 
CFIR implementation approach has 4 components (Plan, Engage, Execute and Reflect/Evaluate), 
that echo the 4 components of the quality assurance paradigm (Plan, Do, Study and Act 
 21 
[PDSA]).  The components of implementation are often done incrementally or in a spiral fashion 
and rarely in sequence.44   
Figure 2: The 5 CFIR Domains 
 
     Execution of implementation correlates with the process domain and is the most difficult to 
measure and is transient by its definition.  The quality of a process depends upon the fidelity of 
the course of action and the degree of engagement of key individuals.  Fidelity is the hard-core 
components of the intervention.  Subjective determination based on organizational 
documentation is the typical assessment.45 The project plan outlined in this proposal will attempt 
to place a numerical value on the implementation process that evaluates CRC-S.  
     Implementation science is the study of methods to promote the systematic uptake of research 
findings into routine practice and hence, to improve the quality and effectiveness of health 
services. Given a refined research-implementation agenda, basic science must undergo pre-
 22 
clinical trials (Type 1 translation) before further clinical research (CR) and effectiveness trials 
formulate an innovation that deserves further attention.  This is where IR (Type 2 translation) 
trials are necessary to bridge the gap between basic science and clinical practice with the 
potential benefit of improved health outcomes.  Whereas CR aims to evaluate a clinical 
intervention, IR focuses on implementation strategy.  Rather than investigation of a procedure, 
test or therapy the emphasis is on clinician, organizational or practice change.  CR is interested 
mainly in health outcomes of the patient.  IR is concerned with the adoption, adherence and 
fidelity of the provider, team or facility.46 
Section 2.10 Hybrid Studies 
     Hybrid studies may involve analysis of both clinical and implementation outcomes. The 
blending of a research design for evaluation of effectiveness and implementation can lead to 
more rapid translational gains when moving an intervention from efficacy research to public 
health impact.  Type 3 hybrid trials involve testing of implementation strategies while collecting 
data on the intervention’s impact on clinical outcomes and will focus on the study design to be 
proposed.  We know that CRC-S is effective in controlled clinical trials, but there is less data 
supporting these methods in the community healthcare setting and in the uninsured patient 
population.  Changes in the effectiveness of the screening intervention may represent a 
vulnerability or enhancement based upon implementation compared to the results of clinical 
trials.47  
Section 2.11 Literature Review: Hybrid Studies of Colorectal Cancer Screening & 
Implementation 
 
     To further investigate the benefit of hybrid designs to aid our understanding of the adoption of 
CRC-S into clinical practice, a literature review was undertaken looking at studies within the 
past 3 years and two search engines, PubMed and the UNC-Chapel Hill Library and the terms 
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“Colorectal cancer screening”, “Implementation outcomes”, and “FQHC”.  Filters were used to 
access English-language, peer-reviewed articles.  Upon review of over 60 abstracts, additional 
filtering was performed to exclude systematic reviews, meta-analyses, pilot trials or designs and 
to include only 6 studies reporting on both clinical and implementation outcomes. 
 












Reuland/ 2017 RCT/2 CHCs; 
34% uninsured 
All PE, PN CRC-S IG 68%; CG 27%. 
PE IG 88%; CG 95%. PN 
100% 
Weiner/2017 Mixed method/3 
FQHCs; Pre-Post 
Survey  
All Practice Facilitation  CRC-S recommendation IG 
29%; CG 15%. Barriers 







PR, PE, PAF, CR, 
PN, Media 
Ave. CRC-S 37.5%; No 
correlation between total # 
of implementation strategies 
and clinic screening rates. 
Correlation between total # 
of fully implemented 
strategies and clinic 
screening rates.  




FIT CFIR domain barriers 
& facilitators  
High implementation clinics 
(59.3% & 81.7% FIT 
completion) had a central 
implementation team & 










CR, PR, PAF, 
Structural barriers, 
Media, PN, PD, CHW 
CRC-S 36.3%; Increasing 
the #s of interventions 
increased the CRC-S rates in 
individual clinics; 16.4% 
increase comparing none vs. 
4 interventions 
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Rohweder/2019 Mixed method, 









CRC-S annual increases of 
3.3% and 8% during 
successive years. PR & PAF 
increased 33% from year 1 
to year 2. PE remained 
constant 100% 
      
   
CFIR: Consolidated Framework for Implementation Research  
CG: Control Group 
CHW: Community Health Worker 
CR: Client Reminder     
FPL: Federal Poverty Level      
IG: Intervention Group 
PAF: Provider Assessment & Feedback 
PD: Professional Development 
PE: Patient Education 
PN: Patient Navigator 
PR: Provider Reminder     
RCT: Randomized Control Trial   
 
                                                                                            
     The literature review highlighted the paucity of hybrid studies that include implementation 
strategies and clinical outcomes.  Although the testing of an intervention while gathering 
information of its clinical effectiveness in the practice setting is relevant and potentially 
timesaving, the design of such studies is more difficult to construct.  Attempting to maximize 
utility for practicing providers is a clear benefit of the hybrid studies described herein.48  
     Three of the six studies above focused on stool testing as the method of CRC-S and three 
others included colonoscopy.  The study settings were FQHCs or community health center 
practices and included a significant uninsured population.  Most reported on the CRC-S rate pre 
and post implementation phase or compared screening establishment in different practice 
locations that had various patterns of EBIs.  Four out of the six studies had a mixed methodology 
that interpreted implementation outcomes qualitatively through administered surveys by practice 
participants.  Most of the studies did not clearly define the implementation factors, leading to 
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ambiguity in how their interventions effected the CRC-S rates reported.  Terms such as 
facilitation, structural barriers, media, implementation team and QI tools were vague and left the 
reader unclear as to the outcomes measured.  Only one randomized trial clearly defined the 
interventions of their decision aid (language-appropriate video) and navigator support.  However, 
88% of the intervention group and 95% of the control group both received the pre-clinical visit 
information.  The navigation component was important in mitigating down-stream barriers 
(obtaining the FOBT/FIT kits, forgetting to complete them and/or scheduling screening or 
diagnostic colonoscopy) and was associated with an increased rate of CRC-S.  As 
implementation was observed, it was considered a type 1 “effectiveness-implementation hybrid” 
study.49  
     In summary, the hybrid studies outlined provide additional support to the growing literature 
associating multiple interventions to effectiveness of CRC-S initiatives, within the context of 
FQHCs that care for a large proportion of the uninsured.  All 6 of the studies reported a positive 
correlation of increasing screening through the implementation of multiple methods that included 
patient education and navigation, patient and provider reminders, elimination of structural 
barriers, provider and staff professional development, media exposure, provider assessment and 
feedback, formal commitment, acquisition of funding and support of leadership.  In most cases, 
the analysis of the interventions was qualitative, and survey based.  As the science of 
implementation evolves, the hybrid methodology may contribute to the expanding knowledge 














CHAPTER 3: RESEARCH DESIGN 
 
Section 3.1 Introduction 
 
     Prior to commitment of valuable resources, a pre-trial or program design should be developed 
as a conceptual project based upon underlying logic, theory and prior experimental research.50 
Cancer prevention is a public health fundamental with the premise of implementing EBIs to 
improve the overall health of a community.  To achieve this goal, possible interventions must be 
evaluated carefully to determine whether comprehensive, time-consuming and costly studies are 
justified.51 A feasibility study will be designed to evaluate implementation of MLIs to improve 
rates of CRC-S, at a community health clinic that cares for 100% uninsured patients.  A hybrid 
design will be outlined to determine whether cancer prevention interventions will translate into 
real-world effectiveness.   
     The indications for this feasibility study include few prior trials of this design, a unique focus 
on an uninsured patient population and evaluation of implementation quantitatively and in 
correlation with clinical outcomes (colonoscopy referrals & completed screening procedures).   
The format of the project design is based on the WHO Implementation Toolkit that is subdivided 
into 6 modules for simplicity: contextualizing implementation research issues, developing an 
implementation research proposal, planning and conducting an implementation research project, 
data analysis and presentation, disseminating the research findings and monitoring and 
evaluating an implementation research project.52   The focus will be developing a research 
proposal (Step 2), understanding that this is a sequential process and that to formulate a 
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feasibility study one must have already contextualized the project and with a forward projection 
of the subsequent steps. 
Figure 3. WHO 6 Steps of the Implementation Research Cycle 
 
     
     Inherent with the development of an IR proposal is clearly understanding the environment to 
which the study will be undertaken.  IR is conducted within real world settings and removed 
from the controlled environment of other forms of scientific research.  It is important to 
understand the context in which this program design has developed.  A master’s program 
community clinic practicum experience led to the idea for this proposal.  Contextualizing 
challenges (Step 1) was performed during the author’s practicum and provided the foundation for 
the project plan that followed.  It involved engagement between researchers and implementers, 
identification of current inefficiencies and potential implementation bottlenecks, framing the 
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appropriate research question, highlighting the various methodological approaches to generate 
information, consideration of ethical issues in context and facilitation of mentorship to ensure 
sustained capacity.53  
     The CCHP was founded in 1993 and is part of the North Carolina Association of Free and 
Charitable Clinics (NCAFCC).  The NCAFCC is a nonprofit organization comprised of 87 clinic 
sites throughout the state.  These clinics are part of a network that provide healthcare to the 
under-insured and as is the case with the CCHP, a 100% uninsured patient population.  The 
clinic provided over 9,000 visits in 2018, from the Greater High Point community of over 20,000 
adults.  The clinic has a volunteer board that oversees operations of a tax-exempt (501-C3) 
entity, 13 full-time employees and more then 80 volunteers.  The community clinic receives 
financial support from the Wake Forest Health Network and adjacent High Point Medical Center, 
by way of free rent of the clinic building, laboratory and radiology services.  The High Point 
Community Foundation funds the salaries of the permanent staff.  Provider support was 100% 
volunteer.  Additional budget necessities are raised through annual fundraising activities, special 
grants and United Way contributions.54 Because of financial constraints to pay for coding and 
billing services to support Medicare and Medicaid patients, the CCHP is not a FQHC and 
therefore not eligible for federal or state grants supporting CRC-S.55  
     In discussion with CCHP leaders, funding of a dedicated CRC-S navigator for CRC-S 
implementation was not an option.  Prior to the inception of the feasibility trial, network 
engagement with colonoscopy specialists was able to institute a “navigator-like” system by 
having the trained specialty staff provide one-on-one guidance for vulnerable patients, once a 
referral was ordered.  In addition, the culture of the community clinic emphasized colonoscopy 
as the preferred method of CRC-S.  Without financial clearance from network administration and 
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specialty RVU indirect compensation to specialists, a high percentage of colonoscopy screening 
tests may not have been a viable option.  However, historically the CCHP was not set up for, nor 
had the resources to follow-up positive stool tests and therefore FOBT/FIT was not considered.  
Lack of consistent volunteer support, electronic medical records and a patient population prone 
to having difficulty in general follow-up predicted a low yield to schedule diagnostic 
colonoscopy after a positive stool test or annual routine stool testing.  A “one and done” 
approach by clinic providers to refer their patients for screening colonoscopy was engrained in 
the system.  Unfortunately, 19 referrals for screening colonoscopy, in 2019, did not suggest a 
robust CRC-S program. 
     Prior to developing the research proposal, a support team was organized.  Stakeholders were 
identified that included the principal investigator (PI), clinic executive director and clinic 
medical director.  An internal appointed leader was designated as the project manager (PM), who 
was an experienced clinic staff full-time employee and respected by his peers. Several meetings 
confirmed the limited financial resources and staffing available for implementation of a process 
to improve cancer screening.  However, at the organizational level discussions had previously 
yielded support for an expanded CRC screening program.  Specific funding for this investigation 
was not considered.   
     A Gemba walk and individual staff interviews with triage volunteers, receptionists, 
schedulers, nurse coordinators, on-site translators and volunteer providers enabled an assessment 
of the present cancer screening process.  Baseline CRC-S data was obtained from chart review 
and referral records.  Brainstorming with various staff members conjugated implementation ideas 
that could improve effectiveness.  In consultation with clinic leadership and using the 
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impact/effort matrix methodology, specific interventions were identified for implementation 
given the limitations of the clinic.   
Section 3.2 Study Participants Plan 
 
     The planned research proposal begins by recruitment of patients into the study.  All clinic 
patients that check-in will be assessed for eligibility into the study.   Eligible patients will be 
males and females, ages 45 to 75 years, without prior evidence by history or chart review of prior 
CRC-S (annual stool test, sigmoidoscopy within 5 years and annual stool test or colonoscopy 
within 10 years).  These eligible patients will then be asked if they want to participate in a study 
of CRC-S.  If the patient agrees, then a consent will be obtained and a demographic survey will 
be completed to identify ethnicity, educational level, literacy level, language preference, income 
and current employment status.  All patients using the CCHP for their medical healthcare home 
are uninsured, by screening documentation prior to being accepted as a patient at the clinic and 
all must reside within the Greater High Point area.  This study population will then be 
randomized to an experimental cohort (Group B: patient education) versus a control cohort 
(Group C: no patient education).  If the patient declines study enrollment for randomization, a 
provider reminder is still placed on the chart and the patient will proceed with a normal clinic 
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Section 3.3 Research Design Plan 
     The hybrid project design plan will use a quasi-experimental technique to evaluate the 
implementation interventions of patient triage and randomization, correlating IOCs with the 
COCs of completed colonoscopy screening orders and completed procedures.  In addition, a 
randomized, prospective method will be used to assess the probability of patient education 
influencing CRC-S.  In a quantitative manner, this proposed plan will attempt to show what is 
happening at the clinic level during the process of implementation.    
CCHP Clinic Patients:  Assess for Eligibility 
Eligible Patients:  Age 45-75 & No prior CRC-S 
Provider Reminder Intervention 
Agree to 
Randomization 












Section 3.4 Research Method Plan 
     The rationale behind this complex research design is to obtain both implementation and 
clinical outcome data, concurrently.  Hybrid studies are efficient models when evaluating 
implementation and the impact on clinical effectiveness.  After a 3-month planning phase, the 
execution of the implementation study and data collection will be completed in 6 months, 
followed by a 3-month period of reflection and evaluation.  Implementation will be captured 
quantitatively by assessment of Study Groups A, B & C. The causal model of convergence 
predicts that if the intervention of a provider reminder (interpersonal/ provider mediated) and a 
randomization intervention (intrapersonal/patient mediated) are interdependent, then Study 
Groups B + C, undergoing both interventions should correlate more positively with COCs than 
Study Group D, in which patients only had a provider reminder, having refused entry into the 
randomized study.   Fidelity of the randomization process will be captured following patient 
consent for participation in the study.  Correlation of implementation outcomes with clinical 
outcomes will attempt to define the importance of IR, when performing effectiveness trials. 
Randomization of Study Groups B & C will identify the importance of the independent variable 
of patient education, as it relates to the dependent variable of CRC-S.      
Section 3.5 Data Collection Plan 
     Data collection will be built into the routine workflow of the clinic, so as not to disrupt the 
usual patient-provider interaction and to facilitate tabulation by the PM (See Appendix 1).  As 
part of the hybrid study, implementation and clinical outcomes (IOCs & COCs) will be identified 
on the clinic worksheet (CWS; See Appendix 2).  The CWS will be formulated by the PI and 
processed by the PM during the planning phase, in an attempt to standardize the data collection 
and minimize bias.  The current CWS will be revised to include red highlighted line items 
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(IOCs) to document a provider reminder that colonoscopy is due, and randomization has 
occurred.  In addition, the CWS will include red highlighted line items (COCs) for a 
colonoscopy referral order and one for colonoscopy procedure completed.  Staff members will be 
trained to review charts to determine patient eligibility and to deliver standardized education 
material for screening colonoscopy, developed to include simple pictorials and a consistent 
message. An interpreter will be provided, if necessary.   
     Upon a routine clinic visit, patients will be identified by triage volunteers for eligibility (See 
Implementation Outcome #1: Provider Reminder [Appendix 1]) by assessing their age and prior 
CRC-S through questioning and chart review.  At this point in the process, it will be documented 
on the CWS to alert the provider that screening colonoscopy is due (See blue document icon 
[Appendix 1]; first red line item, CWS IOC #1[Appendix 2]).  Eligible patients will be asked if 
they wish to participate in the CRC-S trial and if they agree, a separate consent will be signed 
and a demographic survey administered, by the triage volunteer.  Clinic patients will then be 
randomized into Study Groups B & C, based upon their odd or even medical record number, to 
receive CRC-S education (See blue document icon [Appendix 1]; second red line item, CWS 
IOC #2 [Appendix 2]).  Eligible patients that refuse study entry will still be labeled as needing 
CRC-S (provider reminder) and proceed with a routine clinic visit.  A standardized presentation 
using simple pictorials and a language-sensitive description (See Implementation Outcome #2: 
Patient Education [Appendix 1]) will then act as a decision aid for the participating patients 
selected for education.  The provider, un-blinded to the randomization will then interact with the 
patient during their routine clinic visit.  At the end of the clinic visit the provider will signify on 
the CWS whether a screening colonoscopy will be ordered (See blue document icon [Appendix 
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1]; third red line item, CWS COC #1 [Appendix 2]).  The patient will then check-out.  Both 
IOCs and the first COC will be documented on the CWS.   
     The PM will collect copies of the CWS and demographic participant surveys on a daily basis, 
tabulate results and confirm with the scheduler that a specialist referral has been made, if a 
screening colonoscopy order placed. Accuracy of the triage eligibility determination and 
randomization process will be assessed by the PM, after review of all patient charts.  Completion 
of screening colonoscopy will be documented by the PM during monthly follow-up contact with 
specialists (See forth red line item, CWS COC #2 [Appendix 2]). 
Section 3.6 Data Analysis Plan 
      
     The first implementation outcome (IOC #1; provider reminder) will assess all eligible 
patients. Study Group A, those patients that subsequently refuse the randomization intervention 
and who undergo a routine clinic visit will be compared to Study Groups B+C (patients who had 
a provider reminder (IOC #1) and randomization (IOC #2), to determine their association with 
COCs (colonoscopy referral and completion rates).  The randomized Study Groups B & C will 
be compared to one another to analyze the effect of patient education on choosing colonoscopy 
screening.  Demographic subgroup analysis of the randomized groups will be performed.  Means 
and standard deviations will be calculated, as appropriate to evaluate age, race, socioeconomic 
status, etc.                                                                          
     A power calculation, estimating a 50% referral rate will maximizes the sample size.  In order 
to ensure that the 95% confidence interval estimate of the proportion of patients agreeing for 
CRC-S referral is within 5% of the true population, a sample size of 385 is needed.  This sample 
size goal is reachable within the 6-month time frame of the study, with 3 patients per clinic day 
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necessary for enrollment.  Additional analysis will be performed by the biostatistical team 
brought on-board during the planning phase. 
Section 3.7 Quality Management Plan 
     A system will be in embedded within the proposal to ensure the IR meets or exceeds 
scientific, regulatory and ethical standards.  Initial project development will involve overall 
review of the protocol by the research team to ensure consistency and rigor.  During the planning 
phase of the proposal, standard operating procedures will be designated that will include training 
of volunteer staff to comply with the triage intervention and patient education, as well as alerting 
the providers about changes to the CWS and informing them of the overall project design.  The 
data collection process will be reviewed and the revised CWS validated.  Although everyone 
participating with the study will be involved with ensuring quality, it will be the primary 
responsibility of the PM.  During the implementation phase, the PM will collect copies of the 
CWS and patient surveys at the end of each day and record the information on a spread sheet.  
The data will include the patient’s medical record number and demographics. IOCs and the first 
COC will be transferred to a spreadsheet. The second COC, colonoscopy completion, will be 
discoverable by the PM at monthly intervals by chart review (colonoscopy report) or direct 
communication with the specialty office.  The PM will be able to assess quality assurance issues 
with the triage volunteers and schedulers daily and with specialty offices monthly, monitoring 
the office process in real-time.  During the implementation phase, the spreadsheet will be 
emailed to the PI for oversite and routine discussion about potential problems regarding the 
process on a weekly basis.  This dual quality management system between the PM and PI will 
establish rigor, consistency of protocol and adherence to standard operating procedures.   
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Figure 5. Quality Assurance Process 
 
 
Section 3.8 Ethics Plan 
     The proposed feasibility study interventions may not translate to a formal research trial, nor 
am I certain of its impact.  Therefore, key principles of ethical conduct of research will be 
followed.  To ensure social justice, all eligible clients will be reminded if due for CRC-S upon 
arrival for a routine visit and the provider notified, as well.  The concept of beneficence will be 
upheld, as the study aims to promote the health of all enrolled participants by encouraging cancer 
screening.  It is unclear how patient education regarding screening colonoscopy and not stool 
testing (unavailable at the clinic site) will have on clinical outcomes of colonoscopy referral and 
completion of the procedure.  Therefore, a randomized study has been formulated.  A consent 
process will be put in place so that a patient has the opportunity to be fully informed about 
receiving such information and that it does not impinge upon personal rights to decline or accept 
screening colonoscopy.  A separate voluntary consent form will be established for the patient to 
sign that will become part of the permanent record and confidentiality will be ensured.  Because 
our research design involves collecting data on human subjects an ethical review will be 
performed.  The study protocol will be submitted for approval to the appropriate institutional 
review board prior to formal implementation to confirm the protection, dignity, rights and safety 





























     As a public health leader, my involvement to study and also improve CRC-S, at the 
community level has reinforced many core ethical values.  Not proposing a plan to encourage 
clinic patients to have colonoscopy screening when review of organizational data shows that the 
screening rate is lower than that of state or national averages, is an obligatory failure to promote 
equitable distribution of health benefits and opportunities, regardless of the socioeconomic status 
of the patient population.  Furthermore, it reinforces implementation of morally permissible 
plans that are effective, since substantial human and economic costs are associated with such 
measures and leadership must steward responsible use of scarce resources.  Finally, from an 
ethical standpoint, it will be crucial to provide transparency and accountability of the project to 
build community and patient trust of the organization and healthcare providers.56 
     Action guideline recommendations to support future research designs may include informing 
the public about benefits of CRC-S, engaging with the community to identify and address health 
problems and promoting access to other social resources.  Other important considerations include 
embedding a continuous quality improvement process within the research design and 
maintenance of management capacity to promote organizational ethical conduct.  Future work 
should consider incorporating fundamentals of public health within the design to promote not 



















CHAPTER 4: PROJECT PLAN  
 
Section 4.1 Project Plan (See Appendix 3) 
     The project plan will establish a timeline to guide the implementation and monitoring of the 
project.  It will define the roles and responsibilities of the research team members and the 
important milestones to be reached.  Certain research team members will be more involved 
during different phases of the project plan.  However, this feasibility study is intentionally 
narrow in scope and budget and therefore the key stakeholders are involved throughout.  
Community input will be sequestered initially and biostatistical analysis important during the 
pre-implementation and evaluation phases.  Certainly, the proposal and project plan could not be 
possible without direction from the advisory committee, during the pre-implementation phase.  
Certain milestones include the completion of the proposal/master’s thesis and completion of 
implementation study group goals. 
Section 4.2 Research Team Plan (See Appendix 4) 
     The research team will be a multidisciplinary selection of diverse individuals, involving 
researchers, providers, administrators, program implementers and community members.  The 
collective experiences of the team will allow for an amalgamation of ideas necessary to develop 
a research design suitable to study CRC-S, at the community level.   
Section 4.3 Budget Justification Plan (See Appendix 5) 
          One of the limitations I experienced, in the development of this IR proposal, were the 
limited resources available to design a hybrid study, in the community clinic setting.  Rather than 
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speculate what could be the financial requirements, if the feasibility study proved to be effective 
and expansion to other clinical sites or screening for other cancers considered, my budgetary 
objective was to attempt to formulate a scientifically sound research study with essentially a zero 
budget.  This has been the main challenge of the proposal and of major consternation of its 
author, having no past experience in designing such a study or implementing a project of this 
magnitude.   
     It is impossible to estimate my own time and effort and to incorporate it into a program 
budget.  Initial stakeholder discussions led me to the decision to formulate a research project 
within the context of a community clinic caring for the indigent local population and to do it 
without straining the current workforce or asking for additional scarce or unavailable funding.  In 




















CHAPTER 5: PROJECT SUMMARY & POTENTIAL OUTCOMES 
 
     The importance of this proposal is its potential impact as a model for future IR, in the FQHC 
setting.  The findings of this study will contribute to the current knowledge of cancer prevention 
measures in the underserved patient population.  This feasibility study may discover adoptable 
methods for possible incorporation into front-line processes, in other similar clinic scenarios.   
     This proposal has incorporated 6 steps of conducting an IR project (See Figure 2), with a 
focus on the initial processes (Steps 1 & 2).  Prior to development of the project plan, 
contextualizing challenges was an important first step in overall study design and the intent of 
the preceding practicum experience.  Ultimately, a proposal must be evaluated by reaching its 
research objectives.  Proposal objectives satisfied include a plan to study implementation 
interventions, in a community clinic setting and their impact on CRC-S.  In addition, this hybrid 
model will add substantial evidence of the impact of patient education on the decision-making 
process, as it will be analyzed in a randomized prospective manner, while holding other variables 
consistent.   
     The RE-AIM (Reach, Effectiveness, Adoption, Implementation, Maintenance) framework 
was developed to make research findings generalizable with the goal to make programs more 
acceptable and sustainable in a typical community or clinic setting.58 It can be used to evaluate 
health promotion proposals to determine effectiveness, implementation, improve future 
interventions, guide dissemination and provide useful information to stakeholders or funders.  
The proposal described herein is a project plan mainly concerned with “reach” and “adoption”.  
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The CCHP is the adoption organization, and the end-users of the proposal will be the uninsured 
patients that frequent the clinic. The study will generate data to evaluate “effectiveness” (clinical 
outcomes) and “implementation”.  “Maintenance” of the project plan, or what will happen long-
term, will depend upon capacitance and dissemination. 
     One of the hurdles of public health cancer screening programs for the underserved 
communities is restricted research capacitance. A potential outcome of this proposal will be to 
align with the comprehensive needs of the local research institutes: The  
Clinical and Translational Science Institute (CTSI) of Wake Forest University and the North 
Carolina Translational and Clinical Science Institute (NC TraCS).  Both seek to support 
translational research and have community-based projects involving cancer as a priority.  By 
focusing on the strategic needs of the institutions and strengthening the local research network, it 
is anticipated that the generation of preliminary data from this study will enable this writer and 
other collaborators to submit a funding proposal for a small grant to further evaluate the 
implementation process and its impact on clinical outcomes. 
     Dissemination of study results will be paramount for “maintenance” and expanded “reach” of 
the project plan.  The IR conclusions will be prepared and submitted for publication.  In addition, 
findings will be presented to the High Point Community Foundation, composed of a diverse 
group of community members that have local influence and may offer additional grants to fund 
research on cancer prevention, in the Greater High Point area.  Meetings with network leaders 
will also be scheduled to potentially expand the reach of similar screening initiatives within 
affiliated clinics.  A local media release will also be part of the dissemination process. 
     The Public Health Leadership Program, as part of a master’s degree in public health will 
continue to influence my professional career.  Completing the master’s thesis and research 
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proposal entitled, “Implementation Outcomes as a Predictor of Clinical Outcomes in a North 
Carolina Community Clinic: A Hybrid Study” has reinforced the fundamentals of public health 
and the importance of community involvement to help improve patient well-being through 
cancer prevention measures.  Principles of the Ethical Practice of Public Health recognizes that 
individual health is tied to the health of the community.59 The value of supporting community 
clinics that serve the uninsured supports the fundamental right of all individuals to access 
resources necessary for health.  Collaboration of community members and healthcare networks is 
a key element of future projects impacting patient wellness and public health.   
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Clinical Outcome #2: 
Colonoscopy Procedure 
Complete (Delayed Data 
Collection) 
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APPENDIX 2.  THE COMMUNITY CLINIC OF HIGH POINT CLINIC WORKSHEET PLAN 
 
NAME:  DATE:                           DOB:  
   
TEMP: BP: PULSE: HT: RESP: WT: 
      
 
SMOKE: ETOH:               FEMALE/LMP:  PREG:  
    
 
CAPILLARY BLOOD GLUCOSE (IF DIABETIC):  O2 SATURATION %:  
 
 
IOC #1 COLONOSCOPY SCREENING DUE: YES OR NO   
             Date Last Stool Test: 
             Date Last Sigmoidoscopy: 
             Date Last Colonoscopy: 
 
IOC #2 CONSENT FOR CRC-S STUDY & RANDOMIZATION: YES OR NO 
             Yes & Received Education 
             Yes & Did Not Receive Education 
 
REASON FOR VISIT: 
 
TRIAGE VOLUNTEER SIGNATURE: 
 










COC #1 SCREENING COLONOSCOPY ORDER: YES OR NO 
 







APPENDIX 3.  PROJECT PLAN 
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APPENDIX 4. RESEARCH TEAM PLAN 
 
• Principle Investigator (PI): Meade Palmer, MD, FACS.  
Dr. Palmer will provide clinical expertise, having performed over a thousand 
screening colonoscopies during his career as a general surgeon.  He also brings to 
the table an understanding of the overarching principles and background 
information required to formulate a feasibility study of this type. 
 
• Project Manager (PM): Matt Ridenhour (to be appointed).   
Experienced member of the CCHP with knowledge of staff responsibilities and 
familiar with most of the patients that call the clinic their medical home.  
Appointed as the internal champion of the design project, his main responsibility 
will be to troubleshoot problems that arise during implementation on a daily basis, 
confirm randomization, tabulate data from the CWS, ensure scheduling of 
screening colonoscopy and communicate with the PI on a weekly basis. 
 
• Executive Director (ED): Ms. Molly Jordan.  
Long-standing director, in charge of staffing, budget and overall functioning of 
the CCHP.  Involved significantly during the pre-implementation phase and 
decisions about interventions that could be implemented with efficiency and with 
acceptance by staff and providers.  In addition, her input will be needed for the 
determined CWS changes required for data capture during the usual workflow 
process of a typical clinic visit.  During the implementation phase, her 
responsibility will be to support the PM throughout the data collection process 
and will be a key stakeholder in discussions surrounding data analysis, capacity 
building and dissemination of results. 
 
• Chief Medical Officer (CMO): Michael Hussey, MD. 
Dr. Hussey is a retired neurosurgeon who has volunteered part-time, at the CCHP, 
for many years and is the medical director.  He has an interest in cancer 
prevention.  His advice during the pre-implementation phase will be paramount in 
the decision-making processes leading to other volunteer providers accepting 
changes made to the CWS that will be essential during the data-collection phase.   
He will support the PM, at the clinical level and will work with the PM to ensure 
capture of the delayed clinical outcome of screening colonoscopy completion, as 
often records are directly sent to the provider from the specialist’s office.  Dr. 






• Advisory Committee (Dr. Vaughn Mamlin Upshaw and Dr. Dan Reuland). 
Consultant. 
 
Dr. Upshaw is a professor at the Gillings School of Global Public Health, 
University of North Carolina, and is the PI for the NC Public Health Leadership 
Institute.  Currently, she is my academic advisor in the Master’s in Public Health, 
Public Health Leadership Program.  Dr. Reuland is Clinical Professor of Medicine 
in the Division of General Medicine & Clinical Epidemiology, at UNC.  
Currently, Dr. Reuland has graciously agreed to act as a second reader of my 
master’s paper.  He is the director of the Carolina Cancer Screening Initiative, at 
the Lineberger Cancer Center.  His primary research interests are in cancer 
prevention and control.  Dr. Reuland has published extensively in the field of 
CRC-S and some of his work has focused on developing, testing and 
implementing interventions within health systems. 
 
• President of High Point Medical Center (to be appointed). Consultant.  
 
James Hoekstra, MD, FACEP.  Dr. Hoekstra is an Emergency Room Physician 
who has transitioned into a full-time administrator of the regional medical center, 
affiliated with Wake Forest Healthcare Network.  He reports directly to the Dean 
of Wake Forest Baptist Health and to the President of Wake Forest Baptist 
Medical Center.  Dr. Hoekstra is a key physician leader in the health system and 
his role is to drive growth of clinical programs and integration of network health 
systems. 
 
• Department of Biostatistics (to be appointed). Consultant.  
Additional expertise will be required regarding the analysis of the demographic 
survey data, randomization process, power calculation to determine appropriate 
study size and comparative methods to analyze the subgroups and 
implementation/clinical outcomes.  Part of the healthcare network research 
support team. 
 
• Community Members (to be appointed). 
 
Input from community members will be paramount in the design and planning 
phase of the project.  Their experiences with cancer screening will aid the 
development of the research design plan.  Consideration of the community needs 
will help formulate research methods planning, especially details surrounding the 









% OF FTE # OF MONTHS TOTAL COST 
Principle 
Investigator 
NA NA 12+ 0 
Executive Director $60,000 <1% 12 0 
Medical Director Volunteer <1% 12 0 
Project Manager $40,000 5% 12 $2,000 
CCHP Volunteers NA NA 6 0 
EQUIPMENT/ 
SUPPLIES 
    
Stationary NA NA 12 $200 
CONSULTANT     
Biostatical In Network NA 2 0 
CONTRACTURAL     
Translators In House & 
Telephone 







In Network NA 12 0 
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